» Authors » Cinzia Borghese

Cinzia Borghese

Explore the profile of Cinzia Borghese including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 495
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Casagrande N, Borghese C, Corona G, Aldinucci D
Biomed Pharmacother . 2024 Feb; 172:116296. PMID: 38382330
Ovarian cancer (OC) is the fifth most frequent cause of cancer-related death in women. Chemotherapy agent trabectedin, affecting cancer cells and tumor microenvironment, has been approved for the treatment of...
2.
Casagrande N, Borghese C, Avanzo M, Aldinucci D
Cells . 2023 Dec; 12(23). PMID: 38067159
Classical Hodgkin lymphoma (cHL) is a highly curable disease (70-80%), even though long-term toxicities, drug resistance, and predicting clinical responses to therapy are major challenges in cHL treatment. To solve...
3.
Casagrande N, Borghese C, Corona G, Aldinucci D, Altaf M, Sulaiman A, et al.
J Biol Inorg Chem . 2023 Nov; 28(8):751-766. PMID: 37955736
Three new dinuclear gold(I) complexes (1-3) containing a carbene (1,3-Bis(2,6-di-isopropylphenyl)imidazol-2-ylidene (IPr)) and diphosphane ligands [bis(1,2-diphenylphosphano)ethane (Dppe), bis(1,3-diphenylphosphano)propane (Dppp) and bis[2-(dicyclohexylphosphano)ethyl]amine (DCyPA)], were synthesized and characterized by elemental analysis and, ESI-MS,...
4.
Sulaiman A, Casagrande N, Borghese C, Corona G, Isab A, Ahmad S, et al.
J Med Chem . 2022 Oct; 65(21):14424-14440. PMID: 36278959
A new series of seven gold(I) complexes (-) containing 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene (IPr) and phosphane ligands (L1-L7) were synthesized and evaluated for antitumor activity in ovarian cancer (OvCa) models. The synthesized complexes...
5.
Casagrande N, Borghese C, Aldinucci D
Cancers (Basel) . 2022 May; 14(10). PMID: 35626032
Classic Hodgkin lymphoma is characterized by a few tumor cells surrounded by a protective and immunosuppressive tumor microenvironment (TME) composed by a wide variety of noncancerous cells that are an...
6.
7.
Casagrande N, Borghese C, Gabbatore L, Morbiato L, De Zotti M, Aldinucci D
Int J Mol Sci . 2021 Aug; 22(16). PMID: 34445069
Peptaibols, by disturbing the permeability of phospholipid membranes, can overcome anticancer drug resistance, but their natural hydrophobicity hampers their administration. By a green peptide synthesis protocol, we produced two water-soluble...
8.
Casagrande N, Borghese C, Agostini F, Durante C, Mazzucato M, Colombatti A, et al.
Int J Mol Sci . 2021 Apr; 22(6). PMID: 33809553
A high platelet count is associated with a poor prognosis in ovarian cancer (OvCa). Despite good clinical responses with platinating agents in combination with taxanes, numerous OvCa patients relapse due...
9.
Casagrande N, Borghese C, Favero A, Vicenzetto C, Aldinucci D
Cancer Lett . 2020 Dec; 500:182-193. PMID: 33326840
Classical Hodgkin lymphoma (cHL) tumor cells are surrounded by a protective tumor microenvironment (TME). Trabectedin, an anticancer drug targeting both tumor cells and TME, demonstrated a potent antitumor activity against...
10.
Aldinucci D, Borghese C, Casagrande N
Cancers (Basel) . 2020 Jul; 12(7). PMID: 32630699
Tumor cells can "hijack" chemokine networks to support tumor progression. In this context, the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5) axis is gaining increasing attention, since abnormal...